Skip to main content
Premium Trial:

Request an Annual Quote

SwitchGear, New England Biolabs Collaborate on New Dual Reporter Assay System

NEW YORK (GenomeWeb News) – SwitchGear Genomics today said it has partnered with New England Biolabs to develop a new dual reporter assay system.

The new system leverages SwitchGear's LightSwitch Luciferase Assay System and NEB's BioLux Cypridina Luciferase Assay technology. Combined with "a unique genome-wide promoter reporter collection, the LightSwitch Dual Assay System enables unique multiplexing capabilities in cell-based pathway analysis," SwitchGear said in a statement.

The new system also enables research with cell lines that are challenging to transfect and that may require an internal control to normalize variations in transfection efficiency, the Menlo Park, Calif.-based firm added.

The LightSwitch System includes a genome-wide collection of assay-ready GoClone human promoter and 3' UTR luciferase reporters in combination with optimized LightSwitch Luciferase Assay reagents. It uses a newly developed RenSP luciferase reporter gene "optimized for maximum brightness and sensitivity."

The NEB BioLux Cypridina Luciferase Assay Kit has the reagents required for assaying the activity of the Cypridina Luciferase reporter, SwitchGear said.

Financial terms of the deal were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.